On August 19, Eli Lilly rose 3.49% in regular trading, trading at $1284.99/share, with turnover of $10.69 billion. The stock was buoyed by the S&P 500 Healthcare sector reaching a new all-time high, with Eli Lilly attracting sustained capital inflows as the dominant GLP-1 franchise leader.

Multiple investment banks recently raised their price targets on the stock: Morgan Stanley lifted its target to $1,419, BMO Capital Markets to $1,400, Jefferies to $1,440, and Wells Fargo to $1,330, with the consensus mean target now at approximately $1,345, reflecting strong institutional confidence in the company's growth trajectory.

On the pipeline front, Eli Lilly completed a $10 million upfront payment to AlzeCure Pharma for an Alzheimer's disease collaboration, entered a global ion channel program with OmniAb worth up to $370 million in milestones, and initiated a Phase III trial in China for Brenipatide, its second GLP-1/GIP dual-agonist, targeting adult depression. Truist expects full-year revenue to reach $87.3 billion, above the company's guidance range of $85-$87 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)